Carlsbad, Calif., Dec. 1, 2006 - Invitrogen Corporation (Nasdaq:IVGN), a global leader in life sciences, today announced it has completed its acquisition of Sentigen Holding Corp. in a cash transaction at a price of $3.37 per share, or approximately $25.9 million. At close, Sentigen had cash and cash investments on its books valued at approximately $11 million. Sentigen will become a part of Invitrogen's Discovery Sciences business based in Madison, Wisconsin.
